in silico bio-evolutio - novel AI paradigm for molecular biologybroad
in silico bio-evolutio · Horizon Europe grant · 2023-01-01–2025-05-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
The success of phage therapies relies on correctly matching a therapeutic phage to bacterial strain. However calibration of therapy recipe may last for years. Presented solution enable to accelerate this by in silico simulations on AI platform for in vitro. It is able to find optimal phage that meets the phenotype imposed by the researcher, especially: -predict given phage effectiveness against a specific bacteria strain,-indicate mutations that increase phage effectiveness,-generate explanations for predictions.Currently, this process is performed by wet-lab employees (in vitro). Replacing it with an in silico process will reduce the number 90 out of 100 experiments, significantly accelerating the process and improving phage therapy quality. At the same time, its the basis for modern probiotics (for microbiome modulation). At the same time, it will enable dynamically generate personalized therapies for specific patients. It is a novel endeavor in the area of molecular biology.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CAMINO SCIENCE SP. Z O.O. | PL | coordinator | €1,692,596 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.